novo nordisk semaglutide products and competitors Company of the year 2023: – Riding the wave Novo Nordisk is proactively protecting

S.BartelsmanJ

The study included 1 511 637 eligible patients with type 2 diabetes without prior diagnosis of any eye disorder who were prescribed antidiabetic medications, including 82 972 patients prescribed semaglutide or tirzepatide (63 926 patients [77.05%] prescribed semaglutide, 3815 patients [4.60%] prescribed tirzepatide, and 15 231 patients [18.36%] prescribed both medications) and 1 428 665 patients prescribed other antidiabetic medications

While genetics alone do not predict exact medication response, these insights can support a more informed conversation with your provider about realistic timelines and potential optimization strategies

Safety and Tolerability Profile The safety profile of tirzepatide across clinical trials has been generally consistent with other incretin-based therapies

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K